GlassScriptPhysician profile
Nagma Kc
NPI 1346783669
$1,372.78
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $1,041.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $233.86 | 2021-2022 | |
| Abbvie INC. | $219.85 | 2021-2022 | |
| Novo Nordisk INC | $202.43 | 2021-2022 | |
| Lilly USA, LLC | $127.61 | 2022 | |
| Glaxosmithkline, LLC. | $72.46 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $63.98 | 2021-2022 | |
| Pfizer INC. | $53.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.98 | 2021-2022 | |
| Dynavax Technologies Corporation | $40.35 | 2022 | |
| Amgen INC. | $39.92 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.06 | 2021-2022 | |
| Astellas Pharma US INC | $29.88 | 2022 | |
| Esperion Therapeutics, INC. | $22.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.84 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.49 | 2021 | |
| Abbott Laboratories | $20.97 | 2022 | |
| Endo Pharmaceuticals INC. | $20.53 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.10 | 2022 | |
| Amarin Pharma, INC. | $15.08 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagma Kc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.